ReviewImmunity, inflammation and disease2023
The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer.
Review in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Antitumor effects of acupuncture and moxibustion: from immune modulation to tumor microenvironment remodeling.Frontiers in immunology · 2026Review
- Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer.Molecular biology reports · 2025Article
- TLR5 activation in respiratory epithelial cells orchestrate mucosal Th17 response through both indirect and direct pathways.Respiratory research · 2025Article
- The Emerging Mechanisms and Therapeutic Potentials of Dendritic Cells in NSCLC.Journal of inflammation research · 2025Review
- The immune microenvironment of lung adenocarcinoma featured with ground-glass nodules.Thoracic cancer · 2024Review
- The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer.Immunity, inflammation and disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dendritic cell (DC)-T cell axis is a bridge that connects innate and adaptive immunities. The initial immune response against tumors is mainly induced by mature antigen-presenting DCs. Enhancing the crosstalk between DCs and T cells may be an effective approach to improve the immune response to non-small cell lung cancer (NSCLC). In this article, a review was made of the interaction between DCs and T cells in the treatment of NSCLC and how this interaction affects the treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.